Stoke Therapeutics, Inc. Operating Lease, Expense
Stoke Therapeutics, Inc. (STOK) had Operating Lease, Expense of $86.60 million as of 2026-01-21, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-03
- Stoke Therapeutics, Inc. operating lease, expense for the quarter ending 2020-09-30 was $300.00K.
- Stoke Therapeutics, Inc. operating lease, expense for the quarter ending 2020-06-30 was $300.00K.
- Stoke Therapeutics, Inc. operating lease, expense for the quarter ending 2019-03-31 was $200.00K.
| Period end | Operating Lease, Expense | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month |
|---|---|---|---|---|
| 2026-01-21 | $86.60M 10-Q · filed 2026-08-03 | |||
| 2020-09-30 | $300.00K 10-Q · filed 2020-11-12 | $600.00K derived: sum of 2 quarters · filed 2020-11-12 | $900.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $300.00K 10-Q · filed 2020-08-10 | $600.00K 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $200.00K 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |